By Karen Roman
Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.
The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well as hematological malignancies, the company stated.
“The recommendations for both olverembatinib and lisaftoclax (APG-2575) in the updated guidelines are a testament to our strong and innovative pipeline,” said Dr. Yifan Zhai, Ascentage Pharma’s Chief Medical Officer. “In particular, the CSCO Guidelines’ very first recommendations for lisaftoclax, the second Bcl-2 inhibitor to reach NDA submission anywhere in the world, reflect the clinical experts’ forward-looking recognition of this innovative drug.”
Contact:
